Literature DB >> 18400022

Photodynamic therapy in dermatology--an update 2008.

Annette Klein1, Philipp Babilas, Sigrid Karrer, Michael Landthaler, Rolf-Markus Szeimies.   

Abstract

SUMMARY: Photodynamic therapy (PDT) is used for the prevention and treatment of non-melanoma skin cancer. Until recently, clinically approved indications have been restricted to actinic keratoses, nodular and superficial basal cell carcinoma, and--since 2006--Bowen disease. However, the range of indications has been expanding continuously. PDT is also used for the treatment of non-malignant conditions such as acne vulgaris and leishmaniasis, as well as for treating premature skin aging due to sun exposure. Here, PDT is used for the stimulation of immunomodulatory effects in contrast to the induction of necrosis and apoptosis as produced in the treatment of skin tumors. The porphyrin precursor 5-aminolevulinic acid (ALA) or its methyl ester (MAL, so far the only approved formulation in Europe) is applied topically as photosensitizer to exclude systemic reactions. Possible light sources include lasers as well as incoherent light sources; irradiation with incoherent light sources is cheaper and more appropriate for large treatment areas. The main advantages of PDT in comparison to other treatment modalities are its excellent cosmetic results and its high remission rates despite low invasiveness.This article provides up-to-date information about PDT with focus on recently published studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400022     DOI: 10.1111/j.1610-0387.2008.06697.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  9 in total

1.  [Incoherent light in dermatology].

Authors:  P Babilas; S Schreml; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2010-02       Impact factor: 0.751

2.  Clinical efficacy of 5-aminolevulinic acid photodynamic therapy in the treatment of moderate to severe facial acne vulgaris.

Authors:  Xiangqi Chen; Hongtao Song; Shengping Chen; Jing Zhang; Gaoxiang Niu; Xiangnong Liu
Journal:  Exp Ther Med       Date:  2015-07-15       Impact factor: 2.447

Review 3.  Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics.

Authors:  Sha Lu; Changming Lu; Junmin Zhang; Yongxuan Hu; Xiqing Li; Liyan Xi
Journal:  Mycopathologia       Date:  2012-10-20       Impact factor: 2.574

Review 4.  The effect of photodynamic therapy on tumor angiogenesis.

Authors:  Ramaswamy Bhuvaneswari; Yik Yuen Gan; Khee Chee Soo; Malini Olivo
Journal:  Cell Mol Life Sci       Date:  2009-03-31       Impact factor: 9.261

5.  Photodynamic therapy with ablative carbon dioxide fractional laser in treatment of actinic keratosis.

Authors:  Yong Hyun Jang; Dong Jun Lee; Jaeyoung Shin; Hee Young Kang; Eun-So Lee; You Chan Kim
Journal:  Ann Dermatol       Date:  2013-11-30       Impact factor: 1.444

6.  Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.

Authors:  P Nowak-Sliwinska; A Weiss; J R van Beijnum; T J Wong; W W Kilarski; G Szewczyk; H M W Verheul; T Sarna; H van den Bergh; A W Griffioen
Journal:  Cell Death Dis       Date:  2015-02-12       Impact factor: 8.469

7.  A 10-Year Retrospective Analysis of Methyl Aminolevulinate Photodynamic Therapy Consultation at the Hospital de Braga.

Authors:  Celeste Brito; Cristina Resende; Pedro Oliveira
Journal:  Dermatol Ther (Heidelb)       Date:  2016-04-16

Review 8.  Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations.

Authors:  Eder Lilia Romero; Maria Jose Morilla
Journal:  Int J Nanomedicine       Date:  2013-08-20

Review 9.  Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma.

Authors:  Enrico Zelin; Iris Zalaudek; Marina Agozzino; Caterina Dianzani; Arianna Dri; Nicola Di Meo; Roberta Giuffrida; Giovanni Francesco Marangi; Nicoleta Neagu; Paolo Persichetti; Ludovica Toffoli; Claudio Conforti
Journal:  Curr Treat Options Oncol       Date:  2021-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.